Top Antibody Drug Conjugates (ADC) Companies

Antibody Drug Conjugates (ADC) Market size was valued at USD 9.7 Billion in 2023 and is poised to grow from USD 11.17 Billion in 2024 to USD 34.66 Billion by 2032, growing at a CAGR of 15.2% during the forecast period (2025-2032).

Investing in the development of antibody drug conjugates for different cancer indications should remain the prime focus of all companies. Market players should also focus on developing antibody drug conjugates for other chronic diseases to expand their business scope. Targeting developing countries could offer good returns on investment in the long run. Collaborations and partnerships could help antibody drug conjugates companies fast-track their R&D process and improve scope of commercialization as well. 'Roche Holding AG (Switzerland) ', 'Daiichi Sankyo Company, Limited (Japan) ', 'Gilead Sciences, Inc. (US) ', 'Takeda Pharmaceutical Company Limited (Japan) ', 'Pfizer Inc. (US) ', 'Astellas Pharma Inc. (Japan) ', 'AstraZeneca (UK) ', 'ADC Therapeutics SA (Switzerland) ', 'ImmunoGen, Inc. (US) ', 'Zydus Group (India) ', 'AbbVie Inc. (US) ', 'Ambrx (US) ', 'LegoChem Biosciences, Inc. (South Korea) ', 'Byondis (Netherlands) ', 'ProfoundBio (US) ', 'RemeGen (China) ', 'Sutro Biopharma, Inc. (US) ', 'Lepu Biopharma Co., Ltd. (China) ', 'Zymeworks Inc. (Canada) ', 'Mersana Therapeutics (US) ', 'Duality Biologics (China) ', 'Lanova Medicines (China) ', 'Exelixis, Inc. (US) ', 'BioNeCure Therapeutics Inc. (US) ', 'Tripartite Therapeutics, Inc. (US)'

Cancer has become a worldwide public health issue as the cases of cancer keep on rising. This surge in prevalence has led to increased oncology research and high demand for drugs and treatments, which in turn is projected to boost sales of antibody drug conjugates as well.

Development of Antibody Drug Conjugates for Other Chronic Indications: Currently, most antibody drug conjugates are targeted towards cancer indications, but antibody drug conjugates companies can explore application in other indications to maximize their business scope going forward. Increasing investments in development of antibody drug conjugates for the treatment of a wide range of chronic diseases will offer multiple rewarding opportunities in the future.

North America is projected to account for a dominant share of the global antibody drug conjugates market. Presence of a strong medical research infrastructure, supportive government funding for research, and rapid adoption of advanced healthcare technologies and products are key factors allowing North America to lead global antibody drug conjugates demand outlook. The United States is forecasted to account for a major chunk of the revenue in this region for antibody drug conjugates companies. Surging prevalence of cancer and growing geriatric population will also boost antibody drug conjugates demand going forward.